Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

Exclusion Criteria

• •PATIENT CHARACTERISTICS:
• •Age
• •Any age
• •Performance status
• •GOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hemoglobin ≥ 9 g/dL
• •Hepatic
• •AST and ALT ≤ 3 times upper limit of normal (ULN)\*
• •Alkaline phosphatase ≤ 3 times ULN\*
• •Bilirubin ≤ 1.5 times ULN NOTE: \* ≤ 5 times ULN if liver metastases are present
• •Renal
• •Creatinine clearance ≥ 45 mL/min
• •Other
• •Not pregnant
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for at least 3 months after study participation
• •Neuropathy (sensory and motor) ≤ grade 1
• •No active infection requiring antibiotics
• •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •At least 3 weeks since prior biologic or immunologic agents for the malignant tumor
• •One prior non-cytotoxic (biologic or cytostatic) regimen for recurrent or persistent disease allowed, including, but not limited to, the following:
• •* Monoclonal antibodies
• •* Cytokines
• •* Small-molecule inhibitors of signal transduction
• •At least 24 hours since prior growth factors
• •No concurrent routine colony-stimulating factors
• •Chemotherapy
• •See Disease Characteristics
• •Recovered from prior chemotherapy
• •No more than 1 prior cytotoxic chemotherapy regimen with either single or combination cytotoxic drug therapy
• •No prior pemetrexed disodium
• •Endocrine therapy
• •At least 1 week since prior hormonal therapy directed at the malignant tumor
• •Concurrent hormone replacement therapy allowed
• •Radiotherapy
• •See Disease Characteristics
• •At least 2 weeks since prior radiotherapy and recovered
• •No prior radiotherapy to ≥ 25% of bone marrow
• •Surgery
• •Recovered from prior surgery
• •Other
• •At least 3 weeks since other prior therapy directed at the malignant tumor
• •No nonsteroidal anti-inflammatory drugs 2-5 days before, during, and for 1-2 days after study drug administration
• •* Concurrent daily low-dose (≤ 325 mg/day) aspirin therapy allowed
• •No prior therapy that would contraindicate study participation